In the case of mTOR (mammalian target of rapamycin) inhibitor, everolimus is approved for the treatment of neuroendocrine tumor and renal cell carcinoma (as single-agent), and breast cancer (in combination with hormonal therapy) [580, 581]. Here, MTOR is linked to neuroendocrine neoplasm.